|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||22.56 - 22.56|
|52-week range||22.56 - 22.56|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||23.37|
|Earnings date||07 Feb 2022 - 11 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Statements during this call, other than statements of historical facts, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties which may cause actual results to differ materially from those such statements express or imply. The availability of competing treatments, including generic versions of Korlym, our ability to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates and oversights and other requirements, and the scope and protective power of our intellectual property.